checkAd

     101  0 Kommentare NovaBay Pharmaceuticals Announces Changes to Its Board of Directors - Seite 3

    NovaBay Pharmaceuticals Forward-Looking Statements

    Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the integration of DERMAdoctor’s business into the Company’s business, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

    Socialize and Stay Informed on NovaBays Progress
    Like us on Facebook
    Follow us on Twitter
    Connect with NovaBay on LinkedIn
    Visit NovaBay’s Website

    Avenova Purchasing Information
    For NovaBay Avenova purchasing information:
    Please call 800-890-0329 or email sales@avenova.com.
    Avenova.com

    Seite 3 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    NovaBay Pharmaceuticals Announces Changes to Its Board of Directors - Seite 3 NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, …